相关实验视频

Updated: Mar 14, 2026

Human Blastocyst Biopsy and Vitrification

Human Blastocyst Biopsy and Vitrification

Published on: July 26, 2019

第一次胚胎移植后的生化或临床妊娠损失不会影响随后的移植结果

Francesca Barrett¹, Erkan Kalafat², Blake Vessa¹

¹IVIRMA Global Research Alliance, IVIRMA New Jersey, Basking Ridge, NJ 07920, USA; Sidney Kimmel Medical College, Thomas Jefferson, Philadelphia, PA 19107, USA.

Reproductive biomedicine online

|March 12, 2026

概括

在冷胚胎移植 (FET) 后的怀孕损失不会增加在随后的FET中损失的风险. 这项研究发现,在连续的FET周期中,患有妊娠流产和植入失败的患者的结果相似.

科学领域:

生殖医学生殖医学
胚胎学胚胎学
临床产科和妇科临床产科和妇科

背景情况:

经常性流产是辅助生殖技术的一个问题.
了解先前的流产对随后的冷胚胎移植 (FETs) 的影响,对于患者咨询和治疗计划至关重要.

研究的目的:

调查第一个冷胚胎移植 (FET) 后的生化或临床妊娠损失是否会影响随后的FET周期中妊娠损失的可能性.
为了比较先前流产后的妊娠损失率与连续FET中的植入失败.

主要方法:

一项回顾性队列研究分析了2103名连续两次接受euploid FETs的患者和282名未经测试的FETs患者的数据.
患者根据第一次FET的结果进行分类:生化妊娠损失,临床妊娠损失或植入失败.
在第二次FET中,这些组之间的怀孕损失率进行了比较.

主要成果:

在欧体FET周期中,在第一次FET后经历生物化学损失的患者随后的损失率为9.9% (生物化学) 和10.5% (临床),与之前植入失败 (9.6%和10.9%) 患者没有显著差异.
同样,在第一次euploid FET后出现临床损失的患者的后续损失率 (11.5%生化,12.5%临床) 与之前植入失败 (9.6%和10.9%) 的患者相似.
这些发现与未经测试的FET周期一致,表明与植入失败相比,在先前的损失后,随后的妊娠损失的风险没有增加.

结论:

经过冷胚胎移植 (FET) 后的生物化学或临床妊娠损失,无论是带有euploid还是未经测试的胚胎,都不会增加随后的FET妊娠损失的风险.
该研究表明,先前的怀孕流产不应该成为继续进行进一步FET周期的威.

关键词:

生物化学妊娠损失的原因临床的怀孕损失临床的怀孕损失胚胎转移是胚胎的转移.在这个过程中,IVF IVF.植入失败可能是植入失败.

更多相关视频

Chromosome Screening of Human Preimplantation Embryos by Using Spent Culture Medium: Sample Collection and Chromosomal Ploidy Analysis

Chromosome Screening of Human Preimplantation Embryos by Using Spent Culture Medium: Sample Collection and Chromosomal Ploidy Analysis

Published on: September 7, 2021

Zygotic Fluorescence Recovery After Photo-bleaching Analysis for Chromatin Looseness That Allows Full-term Development

Zygotic Fluorescence Recovery After Photo-bleaching Analysis for Chromatin Looseness That Allows Full-term Development

Published on: June 12, 2018

相关概念视频

In Vitro Fertilization

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...

Infertility in Females

Infertility in Females

Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Ovarian Cycle

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...